Overexpression or loss of Cdc42 also contributes to the development of some benign diseases through the same or similar signaling pathways as malignant tumors, such as insulin secretion, insulin resistance, airway inflammation and neurodegenerative diseases (Fig.3). Here, CDC42 is linked to cancer.